Welcome to our dedicated page for Neogenomics news (Ticker: NEO), a resource for investors and traders seeking the latest updates and insights on Neogenomics stock.
NeoGenomics, Inc. reports developments in oncology diagnostic testing, cancer genetics and information services. The company serves oncologists, pathologists, hospital systems, academic centers and pharmaceutical firms through cancer-focused laboratory testing, professional interpretation, clinical trial and research services, validation laboratory services and oncology data solutions.
Recurring news themes include clinical revenue trends, next-generation sequencing growth, reimbursement and coverage decisions, and additions to the company’s testing menu. Updates also cover products such as PanTracer LBx, PanTracer Tissue and RaDaR ST, electronic health record access through Epic Aura, research presentations using Oncology Data Solutions, and the operation of CAP-accredited and CLIA-certified laboratory capabilities in the United States and the United Kingdom.
NeoGenomics, Inc. (NASDAQ:NEO) announced plans to release its third quarter 2020 financial results on October 27, 2020. A conference call and webcast are scheduled for 8:30 AM EDT on the same day to discuss the financial results. Investors can access the call by dialing (844) 602-0380 or (862) 298-0970 for international participants. Call replays will be available until November 10, 2020. NeoGenomics specializes in cancer genetics testing and operates multiple accredited laboratories across the U.S. and internationally.